Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children

Ballerini, Marı́a Gabriela; Domené, Horacio M.; Scaglia, Paula; Martínez, A; Keselman, Ana; Jásper, H; Ropelato, María Gabriela

doi:10.1016/j.ghir.2013.08.003

Cited by 10 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum fasting morning samples were obtained at each visit to measure IGF-I and IGFBP-3. These values and those of calculated IGF-I/IGFBP-3 molar ratio were expressed as SDS according to our normal control group, taking into account age and pubertal stage [22]. rhGH was administered subcutaneously daily before bedtime at a dose of 0.33 mg/kg/week in the SGA and TS groups, whereas in GHD patients, the dose ranged from 0.14 to 0.26 mg/kg/week.…”

Section: Methodsmentioning

confidence: 99%

Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the occurrence of abnormally elevated values of biomarkers of growth hormone (GH) action in short children on recombinant human GH (rhGH) therapy. Methods: Sixty-three prepubertal short children were examined: 31 with GH deficiency (GHD), 25 small for gestational age (SGA), and 9 with Turner syndrome (TS). The main outcomes were the following: standard deviation score (SDS) values of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio before, at the 1st and at the 2nd year on rhGH and Δheight (Ht)-SDS to evaluate GH treatment efficacy (adequate 1st-year ΔHt SDS: >0.4 SDS for GHD and >0.3 SDS for non-GHD). Results: Seventy-eight percent of GHD, 78% of SGA and 55% of TS children had adequate 1st-year ΔHt SDS. In GHD, 88% of IGF-I SDS and IGFBP-3 SDS that were ≤–2.0 SDS at baseline normalized on treatment. Abnormal IGF-I values >+2.0 SDS were observed in 52% of SGA and in 55% of TS patients on rhGH. Within each group, the IGF-I/IGFBP-3 molar ratio increased significantly from pretreatment and throughout therapy, remaining within normal range for most patients. ΔIGF-I/IGFBP-3 molar ratio SDS were significantly higher in children with an adequate response (p < 0.01). Conclusion: Non-GHD groups presented markedly elevated concentrations of GH biomarkers on rhGH and normal IGF-I/IGFBP-3 molar ratio in most patients. Since there is a lack of consensus regarding the molar ratio usefulness, we think that interventions towards a more physiological IGF-I serum profile should be implemented.

show abstract

Section: Methodsmentioning

confidence: 99%

Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Apoyando estas hipótesis, nuestro grupo de trabajo observó que la concentración de 17-hidroxiprogesterona (precursor de andrógenos) y de los niveles de IGF-I en niños sanos a edades peripuberales fueron significativamente mayores comparados con prepúberes de menor edad. 21,23 En la pubertad, la concentración de insulina aumentó respecto de la prepubertad, con dimorfismo sexual en la pubertad avanzada. La menor insulinosensibilidad en las niñas puberales, posiblemente, se deba a una mayor secreción de GH en las niñas en la pubertad 29,30 o diferencias en la acción periférica de insulina en ambos sexos.…”

Section: Discussionunclassified

“…Según regresión de Passing-Bablok, la Ins-ECLIA mide un 30% más respecto del método Ins-QML, con sesgo constante negativo de 0,8 µUI/mL. Se obtuvo la siguiente ecuación, que fue utilizada para corregir valores de concentración de insulina obtenida previamente por el método Ins-QML: 23 (Ins-ECLIA (µUI/mL)= 1,30 x Ins-QML (µUI/mL) -0,8. La concentración de insulina poscorrección matemática fue verificada mediante el protocolo EP-28 de las "Clinical and Laboratory Standards Institute Guidelines" (http://clsi.org/).…”

Section: Población Y Métodosunclassified

Concentración de insulina e índices de insulinosensibilidad en niños y adolescentes sanos

et al. 2016

View full text Add to dashboard Cite

“…In support of these hypotheses, our task force observed that 17-hydroxyprogesterone (an androgen precursor) and IGF-1 levels in healthy peripubertal children were significantly higher than those in younger prepubertal children. 21,23 During puberty, insulin increased compared to prepuberty levels, accompanied by sexual dimorphism during late puberty. The lower insulin sensitivity observed in prepubertal girls is likely due to a higher GH secretion in pubertal girls, 29,30 or differences in insulin peripheral action in both boys and girls.…”

Section: Discussionmentioning

confidence: 99%

“…As per the Passing-Bablok regression, the Ins-ECLIA measurement is 30% more accurate than the Ins-QML method, with a constant negative bias of 0.8 µIU/mL. The following equation was established, which had been used to correct insulin levels obtained in advance using the Ins-QML method: 23 Ins-ECLIA (µIU/mL) = 1.30 x Ins-QML (µIU/mL) -0.8. Insulin levels following mathematical correction were verified using the EP-28 protocol recommended by the Clinical and Laboratory Standards Institute Guidelines (http://clsi.org/).…”

Section: Population and Methodsmentioning

confidence: 99%

Insulin level and insulin sensitivity indices among healthy children and adolescents

et al. 2016

View full text Add to dashboard Cite

Introduction. Information on insulin reference values and insulin sensitivity indices in the field of pediatrics is scarce. Objective. To describe insulin range and insulin sensitivity surrogate indices during childhood. Population and methods. Fasting insulin level range and surrogate indices, such as the homeostasis model assessment of insulin resistance (HOMA-IR), among healthy children and adolescents by age, body mass index, pubertal stage (PS), insulin-like growth factor-1 (IGF-1), total cholesterol, and triglycerides. Results. Two hundred and twenty-six healthy children and adolescents (1-18 years old) were included. Insulin increased with age, body mass index, pubertal stage, IGF-1 and triglyceride levels (r 2 = 0.38, p < 0.0001). Prepubertal children > 7.5 years old had higher insulin levels [median (P3 and P97) µIU/mL: 5.0 (1.7-9.6)] than prepubertal children ≤ 7.5 years old [2.9 µIU/ mL (1.3-10.9), p < 0.01]. During puberty (from PS II to PS V), insulin was higher in girls than in boys [7.4 (1.8-16.9) versus 5.8 (1.8-12.9), p < 0.01]. The HOMA-IR index increased in the group of prepubertal children > 7.5 years old: 1.1 (0.3-2.0) versus children ≤ 7.5 years old: 0.6 (0.3-1.4, p < 0.01). The insulin level and HOMA-IR results were higher in pubertal children compared to the prepubertal group (p < 0.001). Conclusions. Known physiological changes were observed in both insulin levels and the HOMA-IR index among children and adolescents. A fasting blood insulin level of 10 µIU/mL in prepubertal children and of 17 µIU/mL and 13 µIU/mL in pubertal girls and boys, respectively, may be considered as an acceptable cut-off value in healthy children. A HOMA-IR value > 2.0 and > 2.6 in prepubertal and pubertal children, respectively, may be considered a warning sign for pediatricians to further investigate insulin resistance.

show abstract

Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children

Cited by 10 publications

References 36 publications

Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy

Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy

Concentración de insulina e índices de insulinosensibilidad en niños y adolescentes sanos

Insulin level and insulin sensitivity indices among healthy children and adolescents

Contact Info

Product

Resources

About